C. Difficile Infection Treatment in Dallas, TX

What Is C. Difficile Infection?

Clostridioides difficile (formerly Clostridium difficile), commonly known as C. diff, is a spore-forming, toxin-producing bacterium that infects the colon and is the leading cause of healthcare-associated infectious diarrhea in the United States. According to the Centers for Disease Control and Prevention (CDC), C. difficile causes nearly 500,000 infections and is associated with approximately 15,000 to 30,000 deaths each year in the U.S. alone. The CDC has classified C. difficile as an "urgent threat" — its highest threat level — due to the severity, frequency, and antibiotic resistance of the infection.

C. difficile infection (CDI) occurs most commonly after antibiotic therapy disrupts the normal, protective bacteria in the gut (the microbiome), allowing C. difficile to proliferate and produce toxins (toxin A and toxin B) that damage the colonic lining. The clinical spectrum of CDI ranges from mild, self-limited diarrhea to severe, life-threatening pseudomembranous colitis, toxic megacolon, sepsis, and death. Recurrent infection — in which CDI returns after successful treatment — is one of the most challenging problems in modern gastroenterology, affecting 20% to 25% of patients after their first episode.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides expert management of both initial and recurrent C. difficile infections for patients throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology. His treatment approach follows the latest evidence-based guidelines from the American College of Gastroenterology (ACG) and the Infectious Diseases Society of America (IDSA).

How C. Difficile Spreads

C. difficile is transmitted through the fecal-oral route, primarily via contact with environmental surfaces contaminated with C. difficile spores. Understanding how the bacterium spreads is essential for prevention.

• Spore formation — C. difficile produces spores — dormant, highly resistant structures that can survive on surfaces such as bed rails, door handles, toilets, and medical equipment for months. Spores are resistant to heat, drying, and most common disinfectants, including alcohol-based hand sanitizers. Only bleach-based (sporicidal) cleaning agents effectively kill C. difficile spores on environmental surfaces.
• Healthcare facility transmission — Hospitals, nursing homes, and long-term care facilities are the primary settings for C. difficile transmission because of the high concentration of antibiotic use, vulnerable patient populations, and shared environments. Healthcare workers can inadvertently transfer spores from patient to patient on their hands.
• Community-acquired infection — While CDI has traditionally been considered a hospital-acquired infection, community-acquired C. difficile infection is increasingly recognized, accounting for approximately one-third of all cases. Community-acquired CDI tends to affect younger, healthier individuals and may occur with less or no antecedent antibiotic exposure.

Symptoms of C. Difficile Infection

The symptoms of CDI can range from mild diarrhea to fulminant, life-threatening colitis. Symptoms typically begin during or within several weeks of antibiotic therapy, though onset can occur up to 2 to 3 months after the last antibiotic dose.

Mild to Moderate CDI

• Watery diarrhea — Three or more unformed (loose or watery) bowel movements per day for two or more consecutive days is the hallmark symptom of CDI. The stool often has a distinctive foul odor.
• Lower abdominal cramping and pain — Mild to moderate abdominal discomfort, typically in the lower abdomen, often accompanies the diarrhea.
• Low-grade fever — A temperature up to 101°F (38.3°C) may be present.
• Nausea and decreased appetite — General malaise, nausea, and reduced food intake are common.

Severe CDI

• Profuse, watery diarrhea — Severe CDI may produce 10 to 15 or more watery bowel movements per day, leading to rapid dehydration and electrolyte imbalances.
• Severe abdominal pain and tenderness — Intense abdominal pain with marked tenderness on palpation suggests significant colonic inflammation.
• High fever — Temperature above 101.5°F (38.5°C).
• Elevated white blood cell count — A markedly elevated white blood cell count (leukocytosis, often greater than 15,000 cells/μL) is a hallmark of severe CDI.
• Bloody stool — While most CDI produces watery (non-bloody) diarrhea, blood in the stool can occur in severe cases.
• Dehydration — Signs include dark urine, decreased urine output, dry mouth, dizziness, and rapid heart rate.

Fulminant CDI

In the most severe cases, CDI can progress to fulminant colitis, which is a life-threatening emergency characterized by hypotension (low blood pressure) and signs of septic shock, ileus (the colon stops moving, and diarrhea may paradoxically decrease or stop), toxic megacolon (dangerous dilation of the colon), and organ dysfunction. Fulminant CDI requires immediate hospitalization, intensive care, and potentially emergency surgery (subtotal colectomy).

Causes & Risk Factors

CDI develops through a well-understood pathogenic sequence: disruption of the normal gut microbiome (most commonly by antibiotics), acquisition of C. difficile spores, germination and proliferation of C. difficile in the colon, and production of toxins A and B that damage the colonic epithelium and trigger inflammation.

The Role of Antibiotics

Antibiotic exposure is the single most important risk factor for CDI. The normal gut microbiome provides a natural defense against C. difficile colonization through a process called colonization resistance. When antibiotics kill large numbers of protective bacteria, C. difficile is able to multiply rapidly and produce disease-causing toxins. While any antibiotic can potentially trigger CDI, the following are most commonly implicated:

• Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) — The antibiotic class most strongly associated with CDI, particularly with the hypervirulent NAP1/BI/027 strain.
• Clindamycin — Historically one of the antibiotics most frequently associated with CDI.
• Broad-spectrum cephalosporins (ceftriaxone, cefazolin)
• Broad-spectrum penicillins (amoxicillin-clavulanate, ampicillin-sulbactam)
• Carbapenems (meropenem, imipenem)

Other Risk Factors

• Age over 65 — Older adults have a significantly higher risk of CDI and CDI-related complications and mortality.
• Hospitalization or healthcare facility residence — Being in a hospital, nursing home, or long-term care facility increases exposure to C. difficile spores.
• Immunosuppression — Patients with weakened immune systems are at higher risk for CDI and more severe disease.
• Proton pump inhibitor (PPI) use — Several studies have associated PPI use with an increased risk of CDI, possibly because reduced stomach acid may allow more spores to survive passage to the colon.
• Inflammatory bowel disease — Patients with ulcerative colitis or Crohn's disease have a higher risk of CDI.
• Prior CDI — A history of previous C. difficile infection is one of the strongest risk factors for recurrence.
• Recent surgery — Gastrointestinal surgery increases CDI risk due to perioperative antibiotic use and hospitalization.

How C. Difficile Is Diagnosed

The diagnosis of CDI requires both clinical suspicion (diarrhea with relevant risk factors) and laboratory confirmation of C. difficile toxin or toxigenic organism in the stool. Testing should only be performed on unformed (loose or watery) stool — testing formed stool is not recommended because it can detect asymptomatic carriers.

Laboratory Testing

• Multi-step algorithm (recommended approach) — A common approach starts with a screening test for glutamate dehydrogenase (GDH). If GDH is positive, a toxin immunoassay (EIA) is performed to detect toxins A and B. If results are discordant, a nucleic acid amplification test (NAAT/PCR) is used as a tiebreaker. This multi-step approach has the best combination of sensitivity and specificity.
• NAAT/PCR alone — Highly sensitive but can detect asymptomatic carriers and may lead to overdiagnosis when used as a standalone test.
• Toxin EIA alone — Highly specific (a positive result strongly confirms active disease) but has lower sensitivity.

Imaging and Endoscopy

• CT scan of the abdomen — May reveal colonic wall thickening and signs of colitis. In fulminant CDI, CT can identify toxic megacolon and perforation.
• Colonoscopy or flexible sigmoidoscopy — Not routinely required but may be performed in atypical presentations. The characteristic finding is pseudomembranes — raised, yellow-white plaques on the colonic mucosa that are virtually pathognomonic for C. difficile colitis.

Treatment Options

Treatment for CDI depends on the severity of the infection, whether it is an initial or recurrent episode, and the patient's overall clinical status. The goals are to eliminate the infection, restore the normal gut microbiome, and prevent recurrence.

General Measures

• Discontinue the inciting antibiotic — Whenever clinically feasible, the antibiotic that triggered CDI should be stopped. This is the single most important initial step.
• Avoid anti-motility agents — Medications such as loperamide (Imodium) should generally be avoided in CDI because they can mask severity and may increase the risk of toxic megacolon.
• Supportive care — Adequate hydration, electrolyte replacement, and nutritional support are essential.

Treatment of Initial Episode

• Fidaxomicin (Dificid) — The ACG and IDSA now recommend fidaxomicin as the preferred first-line treatment for initial CDI. Fidaxomicin (200 mg twice daily for 10 days) is a narrow-spectrum antibiotic that targets C. difficile while preserving much of the normal gut microbiome. Fidaxomicin achieves similar initial cure rates to vancomycin but with significantly lower recurrence rates (approximately 13% vs. 27%).
• Oral vancomycin — Vancomycin (125 mg four times daily for 10 days) acts locally in the intestinal lumen and remains an effective first-line option, particularly when fidaxomicin is not available.
• Metronidazole — No longer recommended as first-line therapy by the ACG or IDSA due to inferior cure rates compared to vancomycin and fidaxomicin.

Treatment of Recurrent CDI

Recurrent CDI occurs in approximately 20% to 25% of patients after the initial episode, and the risk increases to 40% to 65% after a second recurrence.

• First recurrence — Fidaxomicin (standard or extended-pulsed regimen) is preferred. An alternative is a vancomycin tapered and pulsed regimen over several weeks.
• Bezlotoxumab (Zinplava) — A monoclonal antibody that neutralizes C. difficile toxin B, administered as a single IV infusion during CDI treatment. It reduces the risk of recurrence by approximately 40% and is recommended for patients at high risk of recurrence.
• Fecal microbiota transplantation (FMT) — For patients with two or more recurrences, FMT is the most effective treatment available. FMT restores the normal gut microbiome and achieves cure rates of 85% to 90%. It can be delivered via colonoscopy, upper endoscopy, or oral capsules. FDA-approved microbiome-based therapies (such as fecal microbiota, live-jslm [Rebyota] and fecal microbiota spores, live-brpk [Vowst]) are now available as standardized alternatives.

Treatment of Fulminant CDI

Fulminant CDI requires hospitalization, typically in an intensive care unit. Treatment includes high-dose oral vancomycin (500 mg four times daily), intravenous metronidazole (500 mg every 8 hours), and vancomycin retention enemas if ileus is present. Surgical consultation for subtotal colectomy should be obtained early in patients with toxic megacolon, perforation, or clinical deterioration.

Frequently Asked Questions